Browse News

Found 263 articles

• MIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1a

  11/21/2023

  MIRA Pharmaceuticals, Inc. today revealed groundbreaking insights into the cognitively enhancing effects of MIRA1a in normal mice during a presentation at the University of Louisville's Christine Lee Brown Envirome Institute's Grand Rounds.

• MIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern Time

  11/21/2023

  MIRA Pharmaceuticals, Inc. today announced it will host a shareholder update call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern Time.

• MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2

  11/20/2023

  MIRA Pharmaceuticals, Inc., an innovative pre-clinical-stage pharmaceutical company, announced a partnership with MIRALOGX, LLC, an intellectual property holding company established by MIRA's founder.

• United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI

  11/14/2023

  Evoke Pharma, Inc. announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,813,231 titled “Nasal Formulations of Metoclopramide”, pertaining to the Company’s commercially available and FDA-approved nasal formulation of metoclopramide, GIMOTI.

• Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights

  11/14/2023

  Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2023.

• Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results

  11/9/2023

  Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the third quarter ended September 30, 2023.

• CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

  11/7/2023

  CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today reported third quarter 2023 financial results and provided a business update.

• Rampart Health Bursts Out of Stealth Mode to Report 77% Disease Control in Metastatic Cancer from First-in-Human Phase 2 Trial ("Abscopal 5001") of Multiplex Intra-tumoral Immunotherapy (MITI)

  11/6/2023

  Rampart Health announced positive preliminary results of the first-ever prospective trial of a novel treatment delivered directly into cancer at the Society of Immunotherapy in Cancer Annual Meeting.

• Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors

  11/3/2023

  Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced initial safety, pharmacokinetic (PK), pharmacodynamic (PD) and anti-tumor activity data from its ongoing Phase 1/2 clinical trial evaluating XTX202, an investigational tumor-activated, engineered, beta-gamma IL-2, in late line patients with advanced solid tumors.

• Mayo Clinic and Oxford Nanopore announce collaboration to advance precision medicine for cancer and genetic disorders

  10/19/2023

  Mayo Clinic and Oxford Nanopore Technologies, the company delivering a new generation of nanopore-based molecular sensing technology, unveiled a multi-year joint development collaboration to develop new clinical tests for diseases and improve patient care.

• Theralase(R) Files US Patent for Enhanced Immunotherapy

  10/5/2023

  Theralase Technologies Inc. is focused on the safe and effective destruction of various cancers, bacteria and viruses, when light or radiation activated.

• FASENRA met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA)

  9/11/2023

  Positive high-level results from the MANDARA Phase III trial showed AstraZeneca’s FASENRA (benralizumab) met the primary endpoint of the trial and demonstrated non-inferior rates of remission compared to mepolizumab in patients with eosinophilic granulomatosis with polyangiitis (EGPA) who were receiving oral corticosteroids (OCS) with or without stable immunosuppressive therapy.

• New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion

  9/7/2023

  Kodiak Sciences Inc. announced top-line, one-year results for its ABC Platform based investigational therapy tarcocimab tedromer 5 mg from the pivotal BEACON study in patients with macular edema due to retinal vein occlusion.

• MIRA Pharmaceuticals and MZ Group Partner to Strengthen Investor Relations and Shareholder Communication Efforts

  9/5/2023

  MIRA Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company focused on the development and commercialization of a novel synthetic THC analog, announced its strategic partnership with MZ Group, a renowned international investor relations firm.

• MIRA Pharmaceuticals to Participate in 6th Annual Cannabinoid-Derived Drug Development Summit

  8/31/2023

  MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company") will participate in the 6th Annual Cannabinoid-Derived Drug Development Summit taking place September 11-13, 2023 in Boston, MA.

• Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update

  8/31/2023

  Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today reported financial results for the six months ended June 30, 2023 and provided corporate updates.

• MIRA Pharmaceuticals to Host Virtual Roadshow Webinar on Monday, September 11, 2023 at 1:00 p.m. Eastern Time

  8/29/2023

  MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of a novel synthetic THC analog, will host a virtual roadshow webinar on Monday, September 11, 2023 at 1:00 p.m. Eastern Time.

• Opthea Successfully Completes Institutional Offer and Increases Capital Raising to A$90.0m (US$57.6 million¹)

  8/28/2023

  Opthea Limited is pleased to announce the successful completion of the institutional component of the capital raising announced on Thursday, 24 August 2023.

• Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results

  8/14/2023

  Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the second quarter ended June 30, 2023.

• Promising signals of effect in Annexin's RVO-study

  8/11/2023

  Annexin Pharmaceuticals AB announces that an independent evaluation of potential signals of effect has been carried out in the company's Phase 2-study in retinal vein occlusion with the investigational new drug ANXV.